KYVERNA THERAPEUTICS INC (KYTX) Stock Price, Forecast & Analysis
USA - NASDAQ:KYTX - US5019761049 - Common Stock
KYTX Key Statistics, Chart & Performance
The current stock price of KYTX is 6.88 USD. In the past month the price increased by 16.81%. In the past year, price increased by 30.06%.
KYTX Latest News, Press Relases and Analysis
KYTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.43 | 374.44B | ||
| AMGN | AMGEN INC | 13.59 | 159.52B | ||
| GILD | GILEAD SCIENCES INC | 14.9 | 151.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.15 | 109.22B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.27 | 68.07B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 851.12 | 56.90B | ||
| ARGX | ARGENX SE - ADR | 61.62 | 50.87B | ||
| INSM | INSMED INC | N/A | 39.36B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.03 | 34.25B | ||
| NTRA | NATERA INC | N/A | 27.21B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.99B | ||
| BIIB | BIOGEN INC | 9.05 | 22.20B |
Related stock screener links
About KYTX
Company Profile
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Company Info
KYVERNA THERAPEUTICS INC
5980 Horton Street, Suite 550
Emeryville CALIFORNIA US
Employees: 129
Phone: 15106268331
KYVERNA THERAPEUTICS INC / KYTX FAQ
What does KYTX do?
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company is headquartered in Emeryville, California and currently employs 129 full-time employees. The company went IPO on 2024-02-08. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The firm is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Can you provide the latest stock price for KYVERNA THERAPEUTICS INC?
The current stock price of KYTX is 6.88 USD. The price decreased by -1.29% in the last trading session.
What is the dividend status of KYVERNA THERAPEUTICS INC?
KYTX does not pay a dividend.
What is the ChartMill rating of KYVERNA THERAPEUTICS INC stock?
KYTX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the analyst forecast for KYTX stock?
12 analysts have analysed KYTX and the average price target is 23.46 USD. This implies a price increase of 240.99% is expected in the next year compared to the current price of 6.88.
What is KYVERNA THERAPEUTICS INC worth?
KYVERNA THERAPEUTICS INC (KYTX) has a market capitalization of 297.56M USD. This makes KYTX a Micro Cap stock.
What is the Short Interest ratio of KYVERNA THERAPEUTICS INC (KYTX) stock?
The outstanding short interest for KYVERNA THERAPEUTICS INC (KYTX) is 4.15% of its float.
KYTX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to KYTX. When comparing the yearly performance of all stocks, KYTX is one of the better performing stocks in the market, outperforming 94.78% of all stocks.
KYTX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to KYTX. The financial health of KYTX is average, but there are quite some concerns on its profitability.
KYTX Financial Highlights
Over the last trailing twelve months KYTX reported a non-GAAP Earnings per Share(EPS) of -3.68. The EPS decreased by -37.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -70.06% | ||
| ROE | -86.07% | ||
| Debt/Equity | 0 |
KYTX Forecast & Estimates
12 analysts have analysed KYTX and the average price target is 23.46 USD. This implies a price increase of 240.99% is expected in the next year compared to the current price of 6.88.